Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Profit After Tax (2022 - 2025)

Oramed Pharmaceuticals' Profit After Tax history spans 4 years, with the latest figure at $29.3 million for Q4 2025.

  • For Q4 2025, Profit After Tax changed N/A year-over-year to $29.3 million; the TTM value through Dec 2025 reached $77.6 million, changed N/A, while the annual FY2025 figure was $64.0 million, 436.04% up from the prior year.
  • Profit After Tax reached $29.3 million in Q4 2025 per ORMP's latest filing, down from $48.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $48.4 million in Q3 2025 to a low of -$19.6 million in Q3 2024.
  • Average Profit After Tax over 4 years is $2.2 million, with a median of -$3.2 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: soared 870.85% in 2024, then plummeted 597.53% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$12.3 million in 2022, then skyrocketed by 208.49% to $13.3 million in 2023, then tumbled by 247.56% to -$19.6 million in 2024, then skyrocketed by 249.41% to $29.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Profit After Tax are $29.3 million (Q4 2025), $48.4 million (Q3 2025), and $7.5 million (Q2 2025).